Compare BHST & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BHST | ACOG |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | Canada | Canada |
| Employees | 87 | 57 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 110.4M |
| IPO Year | N/A | N/A |
| Metric | BHST | ACOG |
|---|---|---|
| Price | $4.34 | $6.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $16.00 |
| AVG Volume (30 Days) | 25.6K | ★ 76.2K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $146.27 | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.10 | $4.50 |
| 52 Week High | $12.80 | $10.88 |
| Indicator | BHST | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 61.56 |
| Support Level | $4.27 | $6.46 |
| Resistance Level | $5.02 | $7.69 |
| Average True Range (ATR) | 0.12 | 0.54 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 26.34 | 63.64 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.